On July 1, Hims & Hers Health rose 5.12% in regular trading, trading at $37.23/share, with turnover of $340 million. The rally was driven by BofA Securities significantly raising its price target on the stock to $36 from $25, representing a 44% increase, while maintaining a Neutral rating.

According to FactSet data, the stock currently carries an average analyst rating of Hold with a mean price target of $29.27. Notably, the stock is trading above the new BofA target. Analysts have highlighted a growing trend of employers cutting GLP-1 weight-loss drug insurance coverage, which could create new growth opportunities for Hims & Hers as consumers seek alternative access channels for weight management solutions.

The company recently completed its acquisition of Eucalyptus, expanding its consumer health platform into Australia, Canada, Germany, and other international markets. BofA analysts had previously noted that strategic investments in vertical supply chain integration and international expansion could serve as long-term differentiators despite near-term margin pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)